Vaccines-2013 - OMICS Group

Recommendations

Info

Ali Shams et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAAssessment of antibody titers and immunity to Hepatitis B in children after chemotherapyAli Shams, Faeze Salehi, Azam Hashemi, Mahmood Vakili, Fateme Zare and Nasrin EsphandyariShahid Sadoughi University of Medical Sciences and Health Services, IranObjective: There is a decrease in vaccine-specific antibody to certain vaccine-preventable diseases in children after chemotherapy,but the frequency of non-immune patients is not clear. In this case-control study, we investigated protection level to Hepatitis Binfection in children 6 months after completing chemotherapy.Methods: In this study 68 patients with cancer and 68 healthy donors were enrolled. Patients were 1.5 -12 years old with completedstandard chemotherapy at least for 6 months. All the patients and healthy donors were negative for HBsAg and HBeAg and hadreceived Hepatitis B vaccination. IgG antibody concentrations against Hepatitis B Virus (HBV) were determined in the patientsand healthy subjects serum by ELISA method. IgG antibody titer > 10 mIU/ml was considered as baseline protective titer forpreventing HBV infection.Results: Anti-HBs antibody titer in 19.12% of patients was less than 10 mIU/ml and 11.76% of the patients had borderlineantibody titer (10-20 mIU/ml). In healthy subjects 2.94% and 5.88% had antibody titer < 10 mIU/ml and 10-20 mIU/mlrespectively. According to statistical analysis frequency of non immune subjects in children with cancer was significantly higherthan those in healthy children (PV=0.024).Conclusion: Hepatitis B vaccination post-intensive chemotherapy in the children with cancer is strongly recommended.Keywords: Hepatitis B infection, vaccination, cancer, immunity.alishams@ssu.ac.irJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 126
Oladipo Aina et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USASocioeconomic status of women and immunization status of under five children in northernNigeria: A case study of poliomyelitis in Kaduna StateOladipo AinaAhmadu Bello University Zaria Nigeria, NigeriaChildhood illness plays an important role in the adverse health status of children under five years of age in northern Nigeria.Since around 1989, concerted efforts have been made to reduce the problem of infant morbidity and mortality in Nigeria,mainly through routine immunization and supplemental campaigns (door to door), and in spite of a 99% reduction in poliomyelitisprevalence worldwide, Nigeria still accounts for the highest prevalence of circulating wild polio virus in the world and the countryis among the ten countries in the world with vaccine coverage below 50 percent. Mainly epidemiologic and anthropologic studieshave been carried out using the NDH (National Demographic and Health) database to explicate the probable factors responsiblefor these poor indicators of child health, particularly in the north eastern part of Nigeria. This research, using sociological toolsof investigation will attempt an interpretative, critical understanding of the socioeconomic status of women and immunizationstatus of under fives, with particular reference to poliomyelitis, in Kaduna state, north central Nigeria.The study was carried out in Sabongari Local Government Area of Kaduna state, north central Nigeria with an estimatedpopulation of 291,358 (NPC, 2008) among two hundred and seventy two women of childbearing age. Of these, one hundred andtwenty had children who had AFP (poliomyelitis) and one hundred and fifty two women who did not have children with AFP intheir households. The respondents were selected purposively using multi stage sampling procedure, by stratification.Key words: socio-economic status, immunization status, poliomyelitis, northern Nigeria.BiographyOladipo Aina has completed his M.Sc and M.Res at the Ahmadu Bello University, Zaria and University of Aberdeen, Scotland and presently workingon his Ph.D at the University of Aberdeen Scotland. He is presently a Lecturer in the Department of Community Medicine, Ahmadu Bello UniversityZaria where he teaches medical students medical sociology, behavioral science and health education in addition to supervising fi nal year medicalstudents’ projects in Community Medicine . He has published about fi ve articles in local and international journals in addition to working as consultantto many local and international NGOs working in Nigeria in the area of public healthdip.yej2001@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 127
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74:
Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125: Hassen Mamo, J Vaccines Vaccin 2013
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?